[go: up one dir, main page]

DE3783282D1 - Varianten von lav-viren, deren dns- und proteinkomponenten und deren verwendung, insbesondere zu diagnostischen zwecken und zur herstellung von immunogenen zusammensetzungen. - Google Patents

Varianten von lav-viren, deren dns- und proteinkomponenten und deren verwendung, insbesondere zu diagnostischen zwecken und zur herstellung von immunogenen zusammensetzungen.

Info

Publication number
DE3783282D1
DE3783282D1 DE8787401416T DE3783282T DE3783282D1 DE 3783282 D1 DE3783282 D1 DE 3783282D1 DE 8787401416 T DE8787401416 T DE 8787401416T DE 3783282 T DE3783282 T DE 3783282T DE 3783282 D1 DE3783282 D1 DE 3783282D1
Authority
DE
Germany
Prior art keywords
immunogenous
variants
dna
compositions
production
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE8787401416T
Other languages
English (en)
Other versions
DE3783282T2 (de
Inventor
Marc Alizon
Pierre Sonigo
Simon Wain-Hobson
Luc Montagnier
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Institut Pasteur
Original Assignee
Institut Pasteur
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Institut Pasteur filed Critical Institut Pasteur
Publication of DE3783282D1 publication Critical patent/DE3783282D1/de
Application granted granted Critical
Publication of DE3783282T2 publication Critical patent/DE3783282T2/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/70—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving virus or bacteriophage
    • C12Q1/701—Specific hybridization probes
    • C12Q1/702—Specific hybridization probes for retroviruses
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/70—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving virus or bacteriophage
    • C12Q1/701—Specific hybridization probes
    • C12Q1/702—Specific hybridization probes for retroviruses
    • C12Q1/703—Viruses associated with AIDS
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/569—Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
    • G01N33/56983—Viruses
    • G01N33/56988—HIV or HTLV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/10021—Viruses as such, e.g. new isolates, mutants or their genomic sequences
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/10022—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/16011—Human Immunodeficiency Virus, HIV
    • C12N2740/16021—Viruses as such, e.g. new isolates, mutants or their genomic sequences
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/16011—Human Immunodeficiency Virus, HIV
    • C12N2740/16051—Methods of production or purification of viral material

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Virology (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Molecular Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Analytical Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Biomedical Technology (AREA)
  • Hematology (AREA)
  • Medicinal Chemistry (AREA)
  • AIDS & HIV (AREA)
  • Biophysics (AREA)
  • Urology & Nephrology (AREA)
  • Food Science & Technology (AREA)
  • Cell Biology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
DE8787401416T 1986-06-23 1987-06-22 Varianten von lav-viren, deren dns- und proteinkomponenten und deren verwendung, insbesondere zu diagnostischen zwecken und zur herstellung von immunogenen zusammensetzungen. Expired - Lifetime DE3783282T2 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP86401380 1986-06-23

Publications (2)

Publication Number Publication Date
DE3783282D1 true DE3783282D1 (de) 1993-02-11
DE3783282T2 DE3783282T2 (de) 1993-05-27

Family

ID=8196317

Family Applications (1)

Application Number Title Priority Date Filing Date
DE8787401416T Expired - Lifetime DE3783282T2 (de) 1986-06-23 1987-06-22 Varianten von lav-viren, deren dns- und proteinkomponenten und deren verwendung, insbesondere zu diagnostischen zwecken und zur herstellung von immunogenen zusammensetzungen.

Country Status (10)

Country Link
US (5) US5030714A (de)
EP (1) EP0253701B1 (de)
JP (1) JPS63503513A (de)
AU (1) AU621031B2 (de)
DE (1) DE3783282T2 (de)
DK (1) DK175819B1 (de)
ES (1) ES2052591T3 (de)
GR (1) GR3007493T3 (de)
PT (1) PT85148B (de)
WO (1) WO1987007906A1 (de)

Families Citing this family (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9309574B1 (en) 1984-08-22 2016-04-12 The United States Of America As Represented By The Secretary, Department Of Health And Human Services Molecular cloning of HIV-1 from immortalized cell lines
US5034511A (en) * 1987-04-13 1991-07-23 Institut Pasteur Variant of LAV viruses
US5030714A (en) * 1986-06-23 1991-07-09 Institut Pasteur Variant of LAV viruses
US5824482A (en) * 1986-06-23 1998-10-20 Institut Pasteur Purification, cloning, and characterization of a novel human immunodeficiency virus LAVMAL
SE8701765L (sv) * 1987-04-28 1988-10-29 Statens Bakteriologiska Lab Analysmetod och medel foer denna
US5043262A (en) * 1988-05-12 1991-08-27 Dana Farber Cancer Institute Protein, sequences containing the VPU gene therefore, vectors, methods of preparation and use
EP0345375B1 (de) * 1988-06-09 1995-03-22 N.V. Innogenetics S.A. HIV-3-Retrovirus und seine Verwendung
FR2640877A1 (de) * 1988-12-06 1990-06-29 Centre Nat Rech Scient
US5278042A (en) * 1989-02-06 1994-01-11 The United States Of America As Represented By The Department Of Health & Human Services Method for detecting inhibitors of tat protein
FR2644176B1 (fr) * 1989-03-07 1993-10-08 Franceville Ctre Internal Recher Retrovirus viscpz infectant naturellement le chimpanze, fragments d'adn de ce retrovirus, procede de preparation d'une proteine et/ou d'une enzyme de ce virus et leurs utilisations
FR2646606B1 (fr) * 1989-05-03 1994-06-17 Inst Nat Sante Rech Med Retrovirus hautement cytopathogenique hiv-ndk. fragment d'adn de ce retrovirus, procede de preparation d'une proteine et/ou enzyme de ce virus et leurs utilisations
ES2083388T3 (es) * 1989-05-31 1996-04-16 Pasteur Institut Anticuerpos dirigidos contra proteinas y glucoproteinas del retrovirus vih-2 eho - aplicaciones para el diagnostico.
ES2262166T3 (es) * 1989-06-02 2006-11-16 Institut Pasteur Sintesis de proteinas o polipeptidos codificados por un secuencia nucleotidica vih-1, vih-2 o siv.
FR2647809B1 (fr) * 1989-06-02 1991-09-20 Pasteur Institut Amorces oligonucleotidiques pour l'amplification du genome des retrovirus du type hiv-1, hiv-2 et siv, et leurs applications au diagnostic in vitro des infections dues a ces virus
FR2647810B1 (fr) * 1989-06-02 1994-07-22 Pasteur Institut Amorces oligonucleotidiques pour l'amplification du genome des retrovirus du type hiv-2 et siv, et leurs applications au diagnostic in vitro des infections dues a ces virus
US7022814B1 (en) 1992-01-21 2006-04-04 Institut Pasteur And Institut National De La Sante Et De La Recherche Medicale Nucleotide sequences derived from the genome of retroviruses of the HIV-1, HIV-2 and SIV type, and their uses in particular for the amplification of the genomes of these retroviruses and for the in vitro diagnosis of the diseases due to these viruses
JP3907201B2 (ja) 1991-12-23 2007-04-18 カイロン コーポレイション 溶液相サンドイッチハイブリダイゼーションアッセイに用いるためのｈｉｖプローブ
EP0591914B2 (de) * 1992-10-06 2010-02-10 Siemens Healthcare Diagnostics Products GmbH Retrovirus aus der HIV-Gruppe und dessen Verwendung
DE4405810A1 (de) 1994-02-23 1995-08-24 Behringwerke Ag Von einem Retrovirus aus der HIV-Gruppe abgeleitete Peptide und deren Verwendung
EP0787191B2 (de) * 1994-10-20 2011-10-26 Institut Pasteur Nukleotiden-sequenzen aus retroviren-antigenen hiv-i gruppe (oder untergruppe) o
FR2734281B1 (fr) * 1995-05-18 1997-07-25 Commissariat Energie Atomique Fragments d'acide nucleique derives du genome du virus vih-1, peptides correspondants et leurs applications en tant que reactifs d'evaluation du risque de transmission materno-foetale du vih-1
US6001558A (en) * 1997-06-25 1999-12-14 Ortho Clinical Diagnostics, Inc. Amplification and detection of HIV-1 and/or HIV 2
US5891994A (en) * 1997-07-11 1999-04-06 Thymon L.L.C. Methods and compositions for impairing multiplication of HIV-1
DE19850186A1 (de) * 1998-10-30 2000-05-25 Roche Diagnostics Gmbh Neue Primer und Sonden zum Nachweis von HIV
DE19908766C2 (de) * 1999-02-19 2001-02-15 Ulrich Schubert Verwendung synthetischer Vpr-Peptide des Humanen Immundefizienzvirus Typ 1 (HIV-1) zur Entwicklung von therapeutischen und diagnostischen Reagenzien
US6399067B1 (en) * 2000-04-28 2002-06-04 Thymon L.L.C. Methods and compositions for impairing multiplication of HIV-1
US6582920B2 (en) 2000-09-01 2003-06-24 Gen-Probe Incorporated Amplification of HIV-1 RT sequences for detection of sequences associated with drug-resistance mutations
CA2419649C (en) 2000-09-01 2011-03-08 Gen-Probe Incorporated Amplification of hiv-1 sequences for detection of sequences associated with drug-resistance mutations
AU2003298718A1 (en) * 2002-11-22 2004-06-18 University Of Massachusetts Modulation of hiv replication by rna interference
TW200613554A (en) * 2004-06-17 2006-05-01 Wyeth Corp Plasmid having three complete transcriptional units and immunogenic compositions for inducing an immune response to HIV
CN101213212A (zh) 2005-02-15 2008-07-02 西蒙有限公司 削弱hiv-1增殖的方法和组合物
US8405379B1 (en) 2008-09-18 2013-03-26 Luc Montagnier System and method for the analysis of DNA sequences in biological fluids
EP2808387B1 (de) * 2012-01-25 2017-06-21 Japan Science And Technology Agency Oligonucleotid für hiv-nachweis, hiv-nachweiskit und hiv-nachweisverfahren

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8423659D0 (en) * 1984-09-19 1984-10-24 Pasteur Institut Cloned dna sequences
GB8324800D0 (en) 1983-09-15 1983-10-19 Pasteur Institut Antigens
US4784941A (en) 1985-04-08 1988-11-15 Genetic Systems Corporation Expression and diagnostic use of pENV-3 encoded peptides which are immunologically reactive with antibodies to LAV
US4629783A (en) 1985-04-29 1986-12-16 Genetic Systems Corporation Synthetic antigen for the detection of AIDS-related disease
WO1987003908A1 (en) * 1985-12-24 1987-07-02 United States Of America, Represented By The Unite Plasmid and phage clones of human t-cell lymphotropic virus type iii
US4839288A (en) * 1986-01-22 1989-06-13 Institut Pasteur Retrovirus capable of causing AIDS, antigens obtained from this retrovirus and corresponding antibodies and their application for diagnostic purposes
US5034511A (en) * 1987-04-13 1991-07-23 Institut Pasteur Variant of LAV viruses
US5030714A (en) * 1986-06-23 1991-07-09 Institut Pasteur Variant of LAV viruses
US5763160A (en) 1988-02-12 1998-06-09 United Biomedical, Inc. Synthetic peptides and process of using same for the detection of antibodies to human immunodeficiency virus (HIV) gp120 envelope protein, diagnosis of AIDS and pre-AIDS conditions and as vaccines
CA2157900A1 (en) * 1993-03-11 1994-09-15 Angeline Douvas Therapeutic strategies for immunoinfective cluster virus infections

Also Published As

Publication number Publication date
US6426073B1 (en) 2002-07-30
AU621031B2 (en) 1992-03-05
PT85148B (pt) 1990-03-30
EP0253701B1 (de) 1992-12-30
DK175819B1 (da) 2005-03-14
EP0253701A1 (de) 1988-01-20
DK93388A (da) 1988-02-23
AU7546887A (en) 1988-01-12
JPS63503513A (ja) 1988-12-22
US20030224352A1 (en) 2003-12-04
ES2052591T3 (es) 1994-07-16
US5773602A (en) 1998-06-30
GR3007493T3 (de) 1993-07-30
DK93388D0 (da) 1988-02-23
WO1987007906A1 (en) 1987-12-30
PT85148A (en) 1987-07-01
US7767800B2 (en) 2010-08-03
US20020177128A1 (en) 2002-11-28
DE3783282T2 (de) 1993-05-27
US5030714A (en) 1991-07-09

Similar Documents

Publication Publication Date Title
DE3783282D1 (de) Varianten von lav-viren, deren dns- und proteinkomponenten und deren verwendung, insbesondere zu diagnostischen zwecken und zur herstellung von immunogenen zusammensetzungen.
DE58906914D1 (de) Mischkneter-vorrichtung und verfahren zur herstellung von teig, insbesondere für teigwaren.
DE3887625D1 (de) Verfahren zur Herstellung von 1,1,1-Trifluorodichlorethan und von 1,1,1,2-Tetrafluorchlorethan.
DE3750749D1 (de) Modifiziertes Dienpolymer und Verfahren zu seiner Herstellung.
DE3789348D1 (de) Bioverträgliches zusammengesetztes Material und Verfahren zu seiner Herstellung.
DE3580283D1 (de) Biologisch wirksame substanz mit hormonellen eigenschaften, verfahren zu ihrer herstellung und verwendung von histonen fuer medizinische zwecke.
DE69007639D1 (de) Silberkatalysator zur Produktion von Ethylenoxid und Verfahren zur Herstellung davon.
DE3777931D1 (de) Titandioxydsol und verfahren zur seiner herstellung.
ATE82986T1 (de) Feste katalysatorkomponente zur anwendung bei stereospezifischer polymerisation von alphaolefinen, verfahren zur herstellung derselben und verfahren zur polymerisation von alpha-olefinen in ihrer anwensenheit.
DE68927949D1 (de) 3,9-Diphosphaspiroundecane und Verfahren zur Herstellung von 3,9-Diphosphaspiroundecanen
DE3767400D1 (de) Biozide zusammensetzungen und deren verwendung.
DE3877428D1 (de) Kondensationsprodukte von silanol, deren herstellung und verwendungen.
DE3763289D1 (de) Ultrafiltrations-, hyperfiltrations- oder entmineralisierungselement, verfahren zu seiner herstellung und seine verwendung zur aufbereitung von fluessigen, radioaktiven abfaellen.
DE69107031D1 (de) Thexyl-trialkoxysilane, Verfahren zur Herstellung und deren Verwendung.
DE3674582D1 (de) (s)-(-)-1-propyl-2',6'-pipecoloxylidid-hydrochloridmonohydrat, verfahren zu seiner herstellung und es enthaltendes pharmazeutisches praeparat.
DE69009614D1 (de) Verfahren zur Herstellung von (S)-gamma-Hydroxymethyl-alpha,beta-Butenolid.
DE3669507D1 (de) 1-benzyl-2-(n-substituierte)-carbamoyltetrahydroisochinoline und methode zur ihrer herstellung.
ATE53382T1 (de) Diperoxysaeure-vorlaeufer, verfahren zu deren herstellung und deren verwendung in bleichmittelzusammensetzungen.
ATE74487T1 (de) Verfahren zur herstellung und verwendung fester, pflanzenwirksamer zusammensetzungen.
DE3781629D1 (de) Platin-beschichtete platin- und rhodium-katalysatorfasern, ihre herstellung und verwendung zur oxydation von ammoniak.
DE3788205D1 (de) Etikett und Verfahren zu seiner Herstellung.
DE59004582D1 (de) 1,3-Di-arylmethoxy-4,6-dinitrobenzole, Verfahren zu ihrer Herstellung und Verfahren zur Herstellung von 4,6-Diaminoresorcin.
ATE84070T1 (de) Varianten von lav-viren, deren dns- und proteinkomponenten und deren verwendung, insbesondere zu diagnostischen zwecken und zur herstellung von immunogenen zusammensetzungen.
DE3788031D1 (de) Harzzusammensetzungen und Verfahren zu deren Herstellung.
DE68919887D1 (de) Verfahren zur Herstellung von 1-alpha,25-dihydroxy-vitamin D2 und dessen 24-Epimer.

Legal Events

Date Code Title Description
8364 No opposition during term of opposition